FCPM III SERVICES B.V. Long-Term Concentrated

CIK: 0002013410 · Show all filings

Period: Q4 2023 (Next →)

Filing Date: Mar 7, 2024

Total Value ($000): $339,396 (100.0% shares, 0.0% debt)

Holdings (6)

NAMS NEWAMSTERDAM PHARMA COMPANY 38.9%

Value ($000) $132,157 Shares 11,831,461 Est. Cost $9.16 Unrealized 0.0%

DYN DYNE THERAPEUTICS INC 24.0%

Value ($000) $81,543 Shares 6,131,079 Est. Cost $9.77 Unrealized 0.0%

ENGN ENGENE HOLDINGS INC 23.6%

Value ($000) $80,097 Shares 8,677,951 Est. Cost $10.40 Unrealized 0.0%

REPL REPLIMUNE GROUP INC 12.1%

Value ($000) $41,024 Shares 4,866,499 Est. Cost $11.59 Unrealized 0.0%

ENGNW ENGENE HOLDINGS INC 0.7%

Value ($000) $2,446 Shares 3,878,148 Est. Cost $0.63 Unrealized —

— ACHILLES THERAPEUTICS PLC 0.6%

Value ($000) $2,127 Shares 2,390,050 Est. Cost $0.89 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
NAMS	NEWAMSTERDAM PHARMA COMPANY	11,831,461	$132,157	38.9%	$9.16	0.0%	ORDINARY SHARES	N62509109
DYN	DYNE THERAPEUTICS INC	6,131,079	$81,543	24.0%	$9.77	0.0%	COM	26818M108
ENGN	ENGENE HOLDINGS INC	8,677,951	$80,097	23.6%	$10.40	0.0%	COM	29286M105
REPL	REPLIMUNE GROUP INC	4,866,499	$41,024	12.1%	$11.59	0.0%	COM	76029N106
ENGNW	ENGENE HOLDINGS INC	3,878,148	$2,446	0.7%	$0.63	—	W EXP 10/31/2028	29286M113
—	ACHILLES THERAPEUTICS PLC	2,390,050	$2,127	0.6%	$0.89	—	SPONSORED ADS	00449L102